Cabita 500 1 Pcs
Colorectal Cancer: Capecitabine is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. It is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred.
Breast Cancer: Capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated.
Pancreatic Cancer: Capecitabine is indicated for the first line treatment of patients with locally advanced and metastatic pancreatic cancer in combination with gemcitabine.
Oesophagogastric Cancer: Capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer.
Capecitabine is a prodrug of fluorouracil, a pyrimidine antimetabolite, which is metabolised into 5-fluoro-2′-deoxyuridine-5′monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP covalently binds to thymidylate synthase, inhibiting the formation of thymidilate, thus interfering with DNA synthesis. Additionally, FUTP interferes with RNA synthesis.
Dosage & Administration
In case of stage-III colon cancer and locally advanced or metastatic breast cancer: 1.25 gm/m2 twice daily for 14 days, followed by a 7-day interval, given as 3-week cycles for a total 8 cycles .
For metastatic colorectal cancer, in combination therapy it is administered as 0.8-1 gm/m2 twice daily for 14 days repeated after 7 days interval.
* চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
May interact with warfarin and increase bleeding risk. May inhibit CYP2C9 enzyme, and therefore increase levels of substrates such as phenytoin and other substrates of CYP2C9 enzymes. The concomitant use of leucovorin is not recommended as it increases the toxicity of capecitabine without any apparent advantage in response rate.
Capecitabine is contraindicated in patients with known dihydropy rimidine dehydrogenase (DPD) deficiency, it is also contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min), and in patients with known hypersensitivity to Capecitabine.
myocardial infarction, angina; hand-foot syndrome (numbness, tingling, pain, redness, or blistering of the palms of the hands and soles of the feet). This can lead to the disappearance of fingerprints in some patients; diarrhea (sometimes severe), nausea, stomatitis; neutropenia, anemia, thrombocytopenia; Hyperbilirubinemia.
Pregnancy & Lactation
Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Precautions & Warnings
Patients receiving therapy with capecitabine should be monitored by a physician experienced in the use of cancer chemotherapeutic agents. Most adverse reactions are reversible and do not need to result in discontinuation, although doses may need to be withheld or reduced. During therapy, tablets should not be broken to adjust the dose.
Symptoms: Nausea, vomiting, diarrhoea, GI irritation and bleeding, bone marrow depression.
Management: Supportive treatment aimed at correcting the presenting clinical manifestations.
Product should be stored at a dry place of controlled room temperature below 30° C and kept out of the reach of children.
- Type Tablet
- Morbi leo risus
- Porta ac consectetur ac
- Vestibulum at eros